Alpha Tau Medical (DRTS) Cash from Operations (2021 - 2022)

Alpha Tau Medical's (DRTS) quarterly Cash from Operations came in at 8743000.0 in Q2 2022, down 32.77% quarter-over-quarter from 6585000.0 in Q1 2022.

Alpha Tau Medical (DRTS) Cash from Operations (2021 - 2022) Analysis & Trends

Alpha Tau Medical has disclosed Cash from Operations across 2 years of filings, most recently posting 8743000.0 for Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -1.67 Mn
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn -12.20 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -2.49 Mn
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 1.43 Bn
9 Abivax 94.37 Bn 94.37 Bn - -
10 Alpha Tau Medical 2,416.70 -76.42 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2022 -8.74 Mn
Jun 30, 2022 -8.74 Mn
Mar 31, 2022 -6.59 Mn
Mar 31, 2022 -6.59 Mn
Mar 31, 2021 -3.13 Mn
Mar 31, 2021 -3.13 Mn